AU2002356759A1 - 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents - Google Patents

17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents

Info

Publication number
AU2002356759A1
AU2002356759A1 AU2002356759A AU2002356759A AU2002356759A1 AU 2002356759 A1 AU2002356759 A1 AU 2002356759A1 AU 2002356759 A AU2002356759 A AU 2002356759A AU 2002356759 A AU2002356759 A AU 2002356759A AU 2002356759 A1 AU2002356759 A1 AU 2002356759A1
Authority
AU
Australia
Prior art keywords
methylpregnan
dione
alpha
anti
inflammatory agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002356759A
Inventor
Keith Biggadike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB0128852.1 priority Critical
Priority to GB0128852A priority patent/GB0128852D0/en
Priority to GB0200109A priority patent/GB0200109D0/en
Priority to GB0200109.7 priority
Priority to GB0224846.6 priority
Priority to GB0224846A priority patent/GB0224846D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to PCT/EP2002/013489 priority patent/WO2003048181A1/en
Publication of AU2002356759A1 publication Critical patent/AU2002356759A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
AU2002356759A 2001-12-01 2002-11-28 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents Abandoned AU2002356759A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB0128852.1 2001-12-01
GB0128852A GB0128852D0 (en) 2001-12-01 2001-12-01 Novel compounds
GB0200109A GB0200109D0 (en) 2002-01-04 2002-01-04 Novel compounds
GB0200109.7 2002-01-04
GB0224846A GB0224846D0 (en) 2002-10-25 2002-10-25 Chemical compounds
GB0224846.6 2002-10-25
PCT/EP2002/013489 WO2003048181A1 (en) 2001-12-01 2002-11-28 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
AU2002356759A1 true AU2002356759A1 (en) 2003-06-17

Family

ID=27256341

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002356759A Abandoned AU2002356759A1 (en) 2001-12-01 2002-11-28 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents

Country Status (2)

Country Link
AU (1) AU2002356759A1 (en)
WO (1) WO2003048181A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GT200500281A (en) 2004-10-22 2006-04-24 Novartis Ag organic compounds.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
WO2007017670A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2649215A1 (en) 2006-04-21 2007-11-01 Novartis Ag 2,6,9-trisubstituted purine compounds as adenosine aza receptor modulators
DE602007013441D1 (en) 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine as pi3k lipid kinase inhibitor
PT2104535E (en) 2007-01-10 2011-03-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
PE07332009A1 (en) 2007-05-07 2009-07-17 Novartis Ag Pyrazine derivatives as blockers of epithelial sodium channels
WO2009074575A2 (en) 2007-12-10 2009-06-18 Novartis Ag Organic compounds
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
SG172444A1 (en) 2008-12-30 2011-07-28 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
EP2391366B1 (en) 2009-01-29 2012-11-28 Novartis AG Substituted benzimidazoles for the treatment of astrocytomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (en) 2009-08-12 2012-02-29 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
CA2771532A1 (en) 2009-08-17 2011-02-24 Intellikine, Inc. Heterocyclic compounds and uses thereof
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
CN102665715A (en) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 Compositions for treatment of cystic fibrosis and other chronic diseases
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (en) 2011-02-23 2015-11-10 インテリカイン, エルエルシー Heterocyclic compounds and uses thereof
GEP20156285B (en) 2011-02-25 2015-05-11 Aierem Elelsi Compounds and compositions as trk inhibitors
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag Derivatives bicyclic heterocycles for treating pulmonary arterial hypertension
BR112014006223A8 (en) 2011-09-15 2018-01-09 Novartis Ag 6-substituted 3- (quinolin-6-ylthio) - [1,2,4-triazol [4,3-a] pyradines, their uses, pharmaceutical compositions, and combination
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2755652A1 (en) 2011-09-16 2014-07-23 Novartis AG N-substituted heterocyclyl carboxamides
JP6130391B2 (en) 2011-11-23 2017-05-17 インテリカイン, エルエルシー Enhanced treatment regimen using MTOR inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
KR20150001782A (en) 2012-04-03 2015-01-06 노파르티스 아게 Combination products with tyrosine kinase inhibitors and their use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc Combination of kinase inhibitors and uses thereof
WO2014198909A1 (en) 2013-06-14 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Rac1 inhibitors for inducing bronchodilation
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
BR112016023967A2 (en) 2014-04-24 2017-08-15 Novartis Ag pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016024533A2 (en) 2014-04-24 2017-08-15 Novartis Ag amino pyrazine derivatives as phosphatidylinositol 3 kinase inhibitors
AU2014391605A1 (en) 2014-04-24 2016-10-27 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4548M (en) * 1963-06-11
GB1440063A (en) * 1972-08-11 1976-06-23 Glaxo Lab Ltd 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids
YU54476A (en) * 1975-03-31 1982-05-31 Taisho Pharma Co Ltd Process for obtaining 17-ester 21-halo-pregnane
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
WO2002088167A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha

Also Published As

Publication number Publication date
WO2003048181A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
EP1450808B8 (en) Quinazoline derivatives for the treatment of t cell mediated diseases
AU2002308515A1 (en) Pentapeptide compounds and uses related thereto
HK1043127A1 (en) Compounds useful as anti-inflammatory agents.
AU2002334881A1 (en) Composite guidewire
AU2002341873A1 (en) High torque guidewire
AU2002329741A1 (en) Loan securitization pool having pre-defined requirements
EP2311488A3 (en) Vaccine composition
AU2002337935A1 (en) Glycoprotein compositions
AU2002339839A1 (en) Site monitor
AU2001260482A1 (en) Quinazoline derivatives for the treatment of tumours
AU2002355055A1 (en) Polyelectrolyte compositions
AU3268001A (en) Precision stage
AU2002351201A1 (en) Tissue repair
AU2002256690A1 (en) 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
IL208892A (en) Hmg fragments as anti-inflammatory agents
AU2002356951A1 (en) Photocathode
AU2002360606A1 (en) Organizer
AU2001275760A1 (en) 6.alpha., 9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent
EP1352897A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
AU2002359923A1 (en) 6-fluorobicyclo[3.1.0]hexane derivatives
IL159418D0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
AU2002326823A1 (en) 17beta-Hydroxysteroid Dehydrogenase Type 3 inhibitors for the treatment of androgen dependent diseases
AU2002246119A1 (en) Topical composition
AU2002310511A1 (en) Combinations for the treatment of inflammatory disorders
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase